Genentech touts pipeline prospects as doubts fester
Facing mounting pressure from competing therapies, Genentech has outlined plans to have 20 different drug development programs in place by 2008, with 50 different projects underway that would include plans to expand the use of drugs already approved for marketing. Avastin, for example, is in development for a number of new cancer indications. Genentech officials were putting their most ambitious face on their pipeline review as analysts have expressed concerns about the company's ability to keep up its meteoric increase in revenue.
- here's the AP report on Genentech's research plans
Related Articles:
Genentech fights to keep edge in drug development. Report
Genentech hiring researchers in big R&D push. Report
Genentech shifts its focus to immunology. Report
Be the first to comment
More stories about sales and marketing Regulators pipeline Avastin Drug Development pharmaceuticals Genentech analysts
Comments
By Katie B | Posted 12:14am | November 16, 2007
i think you're right on the mark about questioning genentech's pipeline and EPS growth. they took the first step in trimming costs by laying off 45 non-essential workers, basically gutting the library and graphics departments. the layed off employees pulled some shenanigans outlined here http://biotechreview.blogspot.com/ ....some sour grapes, but still some legitimate concerns about costs wiht stagnating earnings.
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets